Details for New Drug Application (NDA): 019389
✉ Email this page to a colleague
NDA 019389 describes BECONASE AQ, which is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. Additional details are available on the BECONASE AQ profile page.
The generic ingredient in BECONASE AQ is beclomethasone dipropionate monohydrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.
The generic ingredient in BECONASE AQ is beclomethasone dipropionate monohydrate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the beclomethasone dipropionate monohydrate profile page.
Summary for 019389
| Tradename: | BECONASE AQ |
| Applicant: | Glaxosmithkline |
| Ingredient: | beclomethasone dipropionate monohydrate |
| Patents: | 0 |
Pharmacology for NDA: 019389
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Suppliers and Packaging for NDA: 019389
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BECONASE AQ | beclomethasone dipropionate monohydrate | SPRAY, METERED;NASAL | 019389 | NDA | GlaxoSmithKline LLC | 0173-0388 | 0173-0388-79 | 1 BOTTLE, PUMP in 1 CARTON (0173-0388-79) / 180 SPRAY, SUSPENSION in 1 BOTTLE, PUMP |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | EQ 0.042MG DIPROP/SPRAY | ||||
| Approval Date: | Jul 27, 1987 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
